Abstracts tagged "Behcet’s syndrome"

Abstract Number: 181 • 2012 ACR/ARHP Annual Meeting
Thiopurine S-Methyltransferase Levels in Patients with Behçet’s Disease
Hakan Emmungil¹, Melike Kalfa², Raika Durusoy³, Figen Yargucu Zihni², Gokhan Keser⁴ and Kenan Aksu², ¹Rheumatology, Mersin State Hospital, Mersin, Turkey, ²Dept. of Internal Medicine, Division of Rheumatology, Ege University, Dept. of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey, ³Department of Public Health, Ege University, Department of Public Health, Ege University, Izmir, Turkey, ⁴Dept. of Internal Medicine, Division of Rheumatology, Ege University School of Medicine, Izmir, Turkey
Background/Purpose: Azathioprine (AZA) is an immunosuppressive agent which is widely used not only for the treatment of Behcet’s disease (BD), but also for the treatment…
Abstract Number: 183 • 2012 ACR/ARHP Annual Meeting
A Strong Association Between HLA-A*26 and Behçet’s Syndrome in Japanese Patients: From Two-Center Cohort Study of Behçet’s Syndrome
Tatsuo Kobayashi¹, Mitsumasa Kishimoto², Kazuki Yoshida¹, Yuri Ohara³, Hiroto Nakano¹, Masahiro Minoda¹, Hideto Oshikawa¹ and Kazuo Matsui¹, ¹Rheumatology, Kameda Medical Center, Kamogawa City, Chiba, Japan, ²Division of Allergy and Rheumatology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ³Allergy and Rheumatology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan
Background/Purpose: An association between Behçet’s Syndrome (BS) and HLA-B*51 is widely reported among many different ethnic groups. Recently, a few reports from Taiwan, Greece and…
Abstract Number: 184 • 2012 ACR/ARHP Annual Meeting
The Retrospective Review of 39 Intestinal Behcet’s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid
Yoshitaka Kimura¹, Kurumi Asako², Hirotoshi Kikuchi², Akiteru Takeuchi³ and Hajime Kono², ¹Department of Internal Medicine, Teikyo University school of medecine, Tokyo, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³6-7-8 Arakawa, Tokyo, Japan
Background/Purpose: To examine the demography, clinical characteristics, features of intestinal lesions, treatment, and prognosis in patients with the intestinal Behcet’s disease currently followed at a…
Abstract Number: 185 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet’s Disease with Uveitis As Main Involvement
M. Victoria Hernández¹, Marina Mesquida², Gerard Espinosa³, Victor Llorens², Laura Pelegrin², Juan D. Cañete⁴, Ricard Cervera⁵, Alfredo M. Adan² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ³Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁵Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: To assess the long-term efficacy and safety of tumour necrosis factor (TNF) antagonists (infliximab [IFX], adalimumab [ADA] and golimumab) for the treatment of patients…
Abstract Number: 2385 • 2012 ACR/ARHP Annual Meeting
Prognostic Impact of HLA-B^*51 and HLA–A^*26:01 On Ocular Behcet’s Disease
Jun Won Park¹, Eun Ha Kang², Hye Won Kim¹, Chaerin Park³, Hyeong Gon Yu³, Eun Young Lee¹, Yun Jong Lee⁴, Eun Bong Lee¹ and Yeong Wook Song⁵, ¹Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ³Ophthalmology, Seoul National University Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: To investigate the prognostic implication of HLA-B*51 and HLA-A*26:01on visual outcome in Korean Behcet’s disease (BD) patients with uveitis. Methods: Seventy-seven Korean BD patients…
Abstract Number: 186 • 2012 ACR/ARHP Annual Meeting
Long-Term Infliximab Therapy in Patients with Behcet’s Disease Is Well Tolerated without Increasing Risk of Serious Infections
Sho Ueda, Hiroshi Tsukamoto, Yasushi Inoue, Masahiro Ayano, Satomi Hisamoto, Naoko Ueki, Atsushi Tanaka, Shun-ichiro Ohta, Naoyasu Ueda, Yojiro Arinobu, Hiroaki Niiro, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Infliximab (IFX) is a monoclonal antibody against tumor necrosis factor-a (TNF-a) and is increasingly used in various immune-related diseases including rheumatoid arthritis (RA), ankylosing…
Abstract Number: 2394 • 2012 ACR/ARHP Annual Meeting
Fibromyalgia in Behçet’s Disease Is Associated with Disease Activity
Meryem Can¹, Fatma Alibaz-Öner², Sibel Yılmaz-Öner³, Birkan İlhan⁴, Tülin Ergun⁵, Gonca Mumcu⁶ and Haner Direskeneli⁷, ¹Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Department of Rheumatology, Marmara University School of Medicine, Turkey, ³Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁴Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, ⁵Dermatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Studies on the relationship between Fibromyalgia (FM), a generalized pain disorder with up to 2% prevelance and Behcet’s Disease (BD), a systemic, inflammatory vasculitis,…
Abstract Number: 2369 • 2012 ACR/ARHP Annual Meeting
Aspects of Innate Immunity in Behçet´s Disease: A Model of Autoinflammatory Disease?
Sandro F. Perazzio¹, Paulo Vitor Soeiro Pereira², Alexandre Wagner S. de Souza³, Antonio Condino-Neto² and Luis Eduardo C. Andrade⁴, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Immunology, ICB IV - Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: Behçet's disease (BD) is a systemic vasculitis of unknown etiopathogenesis. Increased neutrophil activation has been previously shown in BD patients and it is unclear…
Abstract Number: 2370 • 2012 ACR/ARHP Annual Meeting
A Genome-Wide DNA Methylation Study Identifies Significant Epigenetic Changes Across the Genome and in Multiple HLA Loci in Behcet’s Disease
Haner Direskeneli¹, Patrick S. Coit², Filiz Ture-Ozdemir¹, Fatma Alibaz-Oner¹, Guher Saruhan-Direskeneli³, Matlock A. Jeffries⁴ and Amr H. Sawalha², ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Physiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Medicine, University of Oklahoma and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Behcet’s disease (BD) is a systemic vasculitis of poorly understood etiology. Herein, we study the DNA methylome in BD for the first time and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].